Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Palmetto Infusion Services LLC (NPI 1265462659)

Field	Value
Entity Type	Organization
Organization	Palmetto Infusion Services LLC
Address	3105 Sunset Blvd
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Infusion Therapy Clinic/Center
NPI Enumerated	July 3, 2006

Payer Source	Total Paid
Medicaid	$93.6M
Medicare	$0

Key Findings

This entity is effectively a Medicaid-focused infusion provider: there is no Medicare billing on file and reported lifetime Medicaid revenue is $93.6M, indicating the practice’s clinical and commercial footprint is concentrated in the Medicaid market rather than dual Medicare/Medicaid operations. Analysts should treat this as a single-payer (Medicaid) revenue profile when assessing network exposure and contracting leverage.

Revenue is highly concentrated in a small set of high-cost biologic infusions: the precomputed top three Medicaid codes (J2350, J2357, J1745) account for 50.9% of the provider’s total Medicaid revenue. In particular, J2350 generated $24.5M (26.2%), J2357 generated $12.1M (13.0%), and J1745 generated $10.8M (11.6%), making these three drugs the dominant revenue drivers.

The code mix indicates a specialty infusion therapy operation focused on high-cost biologics and immune therapies rather than general ambulatory care: top codes include monoclonal antibodies (J2350, J2357, J2323, J9312), anti-TNF agents and biosimilars (J1745, Q5121, Q5103, Q5104), and multiple intravenous immune globulin codes (J1561, J1568, J1569). Presence of both infusion administration codes (96413, 96365, , ) and high-cost drug codes supports a model centered on frequent, clinic-based IV and subcutaneous specialty drug administration for chronic autoimmune, neurology, and immunodeficiency indications.

This provider appears to be a dominant statewide filer for many of its highest-revenue drugs: it ranks #1 of 1 in-state for J2350, J2357, J3380 and several other top-priced codes, and it ranks #1 of 7 for J1745 at the 100th percentile—described in the source as “notably above typical state volume.” Those rank positions indicate it is often the principal or sole in-state supplier of specific biologics under Medicaid.

There are several statistical outliers in the provider’s activity that warrant attention: 96413 is listed as an “extreme outlier” (rank #2 of 51, 98th percentile) with 14.4K claims and $1.2M revenue, and infusion-additive code 96415 is an “extreme outlier” (rank #1 of 19, 100th percentile) with 8.4K claims and $217.7K revenue. Multiple other administration and home-infusion codes (96365, 96366, S9500, 96401) are described as “notably above typical” or high-percentile, supporting unusually high procedural throughput relative to state peers.

Claim volumes underscore high throughput for recurring specialty treatments: notable counts include 12.4K claims for J2357, 8.3K for J1745, 14.4K for 96413, and 8.1K for 96365, demonstrating both frequent dosing schedules and sizable operational scale for infusion sessions. Combined with the high avg paid/claim for biologics (for example, $13,897 avg paid/claim for J2350 and $4,631 for J3380), the profile reflects a business driven by expensive per-claim therapies delivered at scale.

The provider bills a mix of originator biologics and biosimilars for the same therapeutic class, indicating flexibility in sourcing or payer-driven substitution: examples include original infliximab J1745 ($10.8M) alongside biosimilars Q5121 ($2.4M), Q5103 ($2.0M), and Q5104 ($138.9K). This mix suggests they are an active administrator of both branded and biosimilar infliximab products in the state Medicaid market.

The practice is long-tenured: the NPI was enumerated on 2006-07-03 (~20 years ago), indicating the organization has operated in the market for an extended period, which may support established payer relationships and patient referral patterns for chronic infusion services.

Medicaid: Complete Services Breakdown

Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.

42 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2350	Injection, ocrelizumab, 1 mg	1,760	$13,900	$24.5M
J2357	Injection, omalizumab, 5 mg	12,350	$980	$12.1M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,320	$1,300	$10.8M
J3380	Injection, vedolizumab, intravenous, 1 mg	1,900	$4,630	$8.8M
J2323	Injection, natalizumab, 1 mg	2,690	$2,800	$7.5M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	4,020	$1,620	$6.5M
J0490	Injection, belimumab, 10 mg	3,480	$1,260	$4.4M
J9312	Injection, rituximab, 10 mg	590	$4,680	$2.7M
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	2,060	$1,160	$2.4M
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	1,450	$1,630	$2.4M

Showing 1–10 of 42

Medicaid: Competitive Analysis & Benchmarks

How this provider's Medicaid billing volume and revenue compare to other South Carolina providers billing the same CPT/HCPCS codes.

Claims Volume vs. South Carolina Distribution

Palmetto Infusion Services LLC — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. South Carolina median

42 rows

CPT/HCPCS Code	Description	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	Injection, ocrelizumab, 1 mg	1	10	1,760	$13,900	$24.5M
J2357	Injection, omalizumab, 5 mg	1	10	12,350	$980	$12.1M
J3380	Injection, vedolizumab, intravenous, 1 mg	1	10	1,900	$4,630	$8.8M
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	1	10	4,020	$1,620	$6.5M
J0490	Injection, belimumab, 10 mg	1	10	3,480	$1,260	$4.4M
J2323	Injection, natalizumab, 1 mg	1	10	1,350	$2,790	$3.8M
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	1	10	2,060	$1,160	$2.4M
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	1	10	1,450	$1,630	$2.4M
J0517	Injection, benralizumab, 1 mg	1	10	960	$2,240	$2.2M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1	10	810	$1,040	$1.7M

Showing 1–10 of 42

Related Providers

Other providers that share a Tax Identification Number (TIN) with Palmetto Infusion Services LLC, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kristi Hunter	GA	General Practice Physician	$6.4M	$0
Rachel Tedesco	NC	Nurse Practitioner	$5.7M	$0
Stephen Parks	SC	Family Medicine Physician	$3.9M	$0
Lindsay Gamble	SC	Family Nurse Practitioner	$3.7M	$0
Lisa Sauls	SC	Family Nurse Practitioner	$3.4M	$0
Rosalee Unwin	SC	Family Nurse Practitioner	$2.9M	$0
Whitley Weatherford	SC	Family Nurse Practitioner	$2.7M	$0
Glenda Collins	SC	Family Nurse Practitioner	$2.3M	$0
James Montgomery	SC	Gynecology Physician	$1.9M	$0
Eliza Shinall	GA	Family Nurse Practitioner	$1.5M	$0

Nearby Providers

Other providers in the same ZIP code as Palmetto Infusion Services LLC, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
John Payne	SC	Ophthalmology Physician	$4M	$0
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0

Palmetto Infusion Services LLC — Billing Profile & Reimbursement Data

Sign up for Palmetto Infusion Services LLC — Billing Profile & Reimbursement Data policy alerts

Palmetto Infusion Services LLC — Billing Profile & Reimbursement Data

Sign up for Palmetto Infusion Services LLC — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicaid: Total Revenue Breakdown by CPT/HCPCS Code

Medicaid: Complete Services Breakdown

Medicaid: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References